Tommaso Lupia to Humans
This is a "connection" page, showing publications Tommaso Lupia has written about Humans.
Connection Strength
0.056
-
Personalized stewardship and interdisciplinarity: key elements of COVID-19. Microbes Infect. 2021 Mar-Apr; 23(2-3):104781.
Score: 0.007
-
Giardiasis reactivation during severe SARS-CoV-2 infection. Parasitol Int. 2021 02; 80:102241.
Score: 0.007
-
COVID-19: in the uncertainty, do not try this at home. Intern Emerg Med. 2020 11; 15(8):1599-1600.
Score: 0.007
-
Good times, bad times: A diary of a physician in the COVID-19 era. Eur J Intern Med. 2020 Jul; 77:132-133.
Score: 0.007
-
2019 novel coronavirus (2019-nCoV) outbreak: A new challenge. J Glob Antimicrob Resist. 2020 06; 21:22-27.
Score: 0.007
-
A tinea immune reconstitution inflammatory syndrome in a HIV-positive patient starting combination antiretroviral treatment. G Ital Dermatol Venereol. 2020 Oct; 155(5):695-697.
Score: 0.006
-
Antiviral treatment selection for SARS-CoV-2 pneumonia. Expert Rev Respir Med. 2021 08; 15(8):985-992.
Score: 0.002
-
COVID-19 pneumonia: do not leave the corticosteroids behind! Future Microbiol. 2021 03; 16:317-322.
Score: 0.002
-
Use of exogenous pulmonary surfactant in acute respiratory distress syndrome (ARDS): Role in SARS-CoV-2-related lung injury. Respir Physiol Neurobiol. 2021 06; 288:103645.
Score: 0.002
-
COVID-19: where have the lymphocytes gone? Intern Med J. 2020 11; 50(11):1436-1437.
Score: 0.002
-
Ozone therapy in COVID-19: A narrative review. Virus Res. 2021 01 02; 291:198207.
Score: 0.002
-
Efficacy and safety of interferon-free regimens in patients affected by chronic hepatitis C and psychiatric disorders. J Infect Chemother. 2020 Jan; 26(1):18-22.
Score: 0.002
-
Antiviral treatment with pegylated interferon and clinical outcomes in a cohort of immigrants patients affected by hepatitis delta: A retrospective analysis. J Med Virol. 2019 07; 91(7):1329-1334.
Score: 0.002
-
Retreatment with sofosbuvir/velpatasvir in cirrhotic patients with genotype-4 who failed a previous interferon-free regimen: a case series. Antivir Ther. 2018; 23(6):543-547.
Score: 0.001